Ischemia: Clinical Trials

51 trials for Ischemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

51 terminated. 51 Phase 2, 11 Phase 3, 7 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 251Terminated 51
Phase 311Terminated 11
Phase 17Terminated 7

Follow Ischemia: new trials by email Literature Review of Ischemia trials Research Report on Ischemia

Trials (filtered) newest first · largest first

All 51 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
BI 765845, Placebo matching BI 765845 - Myocardial Infarction
Phase 2TerminatedBoehringer Ingelheim1602023-12-052026-07-27
The Pressure-controlled Intermittent Coronary Sinus Occlusion on VentrIcular PERformance Study
PICSO - Myocardial Infarction
Phase 2TerminatedOxford University Hospitals NHS Trust22021-08-032023-08-21
Prevention of Acute Kidney Injury in Patients With NSTEMI
conestat alfa or placebo - Non-ST Elevation Myocardial Infarction (NSTEMI)
Phase 2TerminatedPharming Technologies B.V.292021-04-212024-04-03
YQ23 Study in Patients With Critical Limb Ischaemia
YQ23, Matching placebo - Critical Limb Ischemia
Phase 1 / Phase 2TerminatedNew Beta Innovation Limited52021-03-102023-12-08
SONOthrombolysis in Patients With an ST-segment Elevation Myocardial Infarction With fibrinoLYSIS (SONOSTEMI-LYSIS) Trial
Definity® with High Mechanical Index Ultrasound - ST Elevation Myocardial Infarction
Phase 2TerminatedUniversity of Alberta412021-02-232026-03-04
COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction
Colchicine - Myocardial Infarction, Acute
Phase 2 / Phase 3TerminatedUniversity Hospital, Montpellier542020-12-042026-06-12
Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
Rivaroxaban, Standard Of Care (SOC) - COVID-19
Phase 2TerminatedCharite University, Berlin, Germany1112020-11-302022-01-12
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus
Phase 2TerminatedPhaseBio Pharmaceuticals Inc.542020-07-152020-12-11
Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia.
Autologous ASC (for Adipose-derived Stem/Stroma Cell) - Critical Limb Ischemia and Peripheral Artery Disease
Phase 2TerminatedUniversity Hospital, Toulouse22020-03-042023-03-31
SYNergy Stent® System Implantation With Mandatory Intra-VascularUltra-Sound Guidance and Dual Anti-Platelet Therapy
Dual Antiplatelet (DAPT) Therapy, The Synergy® stent - Coronary Artery Disease, Atherosclerosis
Phase 2TerminatedHonorHealth Research Institute502018-11-192024-12-27
Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI
Entresto Pill - Myocardial Infarction, Diastolic Dysfunction
Phase 2TerminatedJacob Moller512018-10-122025-01-29
Investigation of Neural Stem Cells in Ischemic Stroke
CTX0E03 Drug Product and delivery device, Placebo - Ischemic Stroke, Chronic Stroke
Phase 2TerminatedReNeuron Limited152018-08-312021-08-13
Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After STEMI
Methotrexate, Placebo, Folic Acid - Myocardial Infarction, Anterior Wall, Myocardial Remodeling, Ventricular
Phase 2 / Phase 3TerminatedUniversity of Sao Paulo352018-04-172021-01-11
DNS-3379 vs. Placebo in Stroke Rehabilitation
DNS-3379, Placebo - Ischemic Stroke
Phase 2TerminatedDart NeuroScience, LLC12017-11-132018-02-01
A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke
Basmisanil, Placebo - Stroke
Phase 2TerminatedHoffmann-La Roche52017-02-202019-01-02
Effect of DLBS1033 After Primary PCI in Patients With STE-ACS
DLBS1033, Placebo, Standard therapy - ST Elevation Myocardial Infarction
Phase 2 / Phase 3TerminatedDexa Medica Group232016-11-012023-09-08
Plerixafor in Diabetic Wound Healing
Plerixafor, Placebo - Diabetes, Wounds
Phase 2TerminatedGian Paolo Fadini252016-06-012019-12-19
HT-3951 vs. Placebo in Stroke Rehabilitation
HT-3951, Placebo - Ischemic Stroke
Phase 2TerminatedDart NeuroScience, LLC612016-02-012018-02-01
A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction
AMI MultiStem cells, Sham - Heart Attack, NSTEMI
Phase 2TerminatedHealios K.K.342015-12-012021-07-22
Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
Ticagrelor, Comparator - Peripheral Artery Disease (PAD)
Phase 2TerminatedAstraZeneca402014-10-202017-07-19

Showing 20 of 51. Sign in to see all of them.

Narrower conditions

Myocardial Infarction (21)  ·  Stroke (9)  ·  Chronic Limb-Threatening Ischemia (7)  ·  ST Elevation Myocardial Infarction (7)  ·  Cardiovascular Diseases (5)  ·  Coronary Artery Disease (5)  ·  Heart Diseases (5)  ·  Peripheral Vascular Diseases (5)  ·  Heart Failure (4)  ·  Ischemic Stroke (4)  ·  Cerebral Infarction (3)  ·  Cerebrovascular Disorders (3)  ·  Infarction, Middle Cerebral Artery (3)  ·  Non-ST Elevated Myocardial Infarction (3)

Broader conditions

Pathologic Processes (51)  ·  Pathological Conditions, Signs and Symptoms (51)  ·  Vascular Diseases (46)  ·  Cardiovascular Diseases (44)  ·  Infarction (38)  ·  Necrosis (38)  ·  Myocardial Ischemia (30)  ·  Heart Diseases (27)  ·  Arterial Occlusive Diseases (13)  ·  Arteriosclerosis (13)  ·  Central Nervous System Diseases (11)  ·  Brain Diseases (10)  ·  Myocardial Infarction (10)  ·  Nervous System Diseases (10)

Interventions

Saline Solution (4)  ·  Endothelium-Dependent Relaxing Factors (2)  ·  Nitrogen (2)  ·  Standard of Care (2)  ·  Ticagrelor (2)  ·  2'-deoxythymidylyl-(3'-5')-2'-deoxyadenosine (1)  ·  Aspirin (1)  ·  Atorvastatin (1)  ·  Clopidogrel (1)  ·  Colchicine (1)  ·  Cool-Down Exercise (1)  ·  Corn Oil (1)  ·  DLBS 1033 (1)  ·  Eptifibatide (1)  ·  Fish Oils (1)

Sponsors

Mallinckrodt (3)  ·  Dart NeuroScience, LLC (2)  ·  Johann Wolfgang Goethe University Hospital (2)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (1)  ·  Angion Biomedica Corp (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  AstraZeneca (1)  ·  Biopure Corporation (1)  ·  Boehringer Ingelheim (1)  ·  Brigham and Women's Hospital (1)  ·  Capricor Inc. (1)  ·  Celularity Incorporated (1)  ·  Charite University, Berlin, Germany (1)  ·  Cook MyoSite (1)

Countries

United States (21)  ·  Canada (8)  ·  France (4)  ·  Germany (4)  ·  Spain (4)  ·  Australia (3)  ·  Poland (3)  ·  South Korea (3)  ·  United Kingdom (3)  ·  Belgium (2)  ·  Brazil (2)  ·  Denmark (2)  ·  Italy (2)  ·  New Zealand (2)  ·  Switzerland (2)

Top investigators

Andreas M Zeiher, MD (2)  ·  A. Gerson Greenburg, MD, Ph.D. (1)  ·  Aline G. Ferrari, MD (1)  ·  Andrew P Levy, MD PhD (1)  ·  Anurag Relan, MD (1)  ·  Bernat Soria (1)  ·  Billy Lau (1)  ·  C. Michael Gibson, M.D. (1)  ·  Chen Shapira, MD (1)

Results publications

PMID 15016484, PMID 16990385, PMID 18032779, PMID 19958867, PMID 20185783, PMID 22936827, PMID 23362308, PMID 23686372, PMID 24152824, PMID 26483108, PMID 27834742, PMID 29629845, PMID 32749459, PMID 33502773, PMID 34233913, PMID 34538132, PMID 35130557, PMID 35244208, PMID 37740111, PMID 38289979, PMID 38419030, PMID 41541089

NIH funding

2015 (1), P50NS044148 (1), P50NS044227 (1), R01NS037666 (1), R01NS045170 (1), R44HL091699 (1), R44HL117572 (1), RC3HL103356-01 (1)